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ADVANCES IN immunosuppression and 
refinements in surgical procedures have 
led to improved organ and patient survival in 
vascularized allograft transplantation. An 
increased understanding of allograft rejection 
mechanisms has made it possible to plan a 
rational program for developing and testing 
new reagents for the reversal of acute rejec-
tion. In the forefront of this generation of 
pharmaceuticals available for treating allo-
graft rejection is the mouse anti-human T-cell 
antibody ORTHOCLONE OKT3 (Ortho 
Pharmaceutical Corp, Raritan, N J). 
In several clinical trials, Orthoclone OKT3, 
in conjunction with azathioprine and steroids, 
has demonstrated a marked ability to reverse 
established acute renal allograft rejection. 1-3 
Clinical trials using this bioreagent in con-
junction with cyclosporine (Cs) and steroids 
have recently been conducted4 in an attempt 
to decrease the high rate of recurrent rejection 
seen in earlier trials using azathioprine and 
steroids. 
We have previously reported the results of 
our pilot, randomized trial using Orthoclone 
OKT3 v high-dose steroids in conjunction 
with Cs and steroids for the treatment of acute 
hepatic allograft rejection.4 This early study 
revealed a higher rate of reversal of rejection 
with Orthoclone OKT3 than with high-dose 
steroids. Using combined data from three 
transplant centers, Cosimi et al5 subsequently 
confirmed our findings in their randomized 
clinical study of Orthoclone OKT3 v high-
dose steroids for reversal of acute liver allo-
graft rejection.5 
In order to better define the conditions for 
Orthoclone OKT3 therapy during allograft 
dysfunction, we further expanded our studies 
to include 52 hepatic and ten renal allograft 
recipients.6 Not only did we document the 
efficacy of Orthoclone OKT3 in reversing 
acute cell-mediated allograft rejection, but we 
found that the high incidence of recurrent 
rejection seen with azathioprine and steroids 
did not occur when Cs and steroids were used 
as baseline immunosuppression. 
In the current report, an additional 105 
patients were treated with Orthoclone OKT3 
for acute hepatic allograft dysfunction. In 
addition to further analysis of the efficacy of 
Orthoclone OKT3 for reversal of acute he-
patic rejection, we have analyzed the impact 
of Orthoclone OKT3 on liver transplantation 
at this institution by taking into account over-
all graft and patient survival. 
MATERIALS AND METHODS 
Case Material 
One hundred fifty-seven hepatic allograft recipients 
received a course of Orthoclone OKT3 during the period 
from November 1984 to December 1985. Follow-up was 
available on alliS? patients up to April 1986. Statistical 
analyses of various parameters were obtained by compar-
ing the study group with a control group consisting of 320 
liver allograft recipients who received transplants during 
the period from August 1983 to December 1985 and who 
were not treated with Orthoclone OKT3. 
Primary Immunosuppression 
The principles of Cs and steroid therapy in the post-
transplant period7 and throughout the period of Ortho-
clone OKT3 therapy,' have been previously detailed. One 
major conclusion from our initial liver studies was that 
maintenance Cs and steroid therapy should be continued 
during Orthoclone OKT3 therapy, but that adjustments 
should be made in order to bring serum Cs up to a 
therapeutic level. 
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Indication and Timing of Orthoclone 
OKTJ Therapy 
The 157 hepatic allograft recipients were treated with 
Orthoclone OKT3 from one to 460 days after transplan-
tation. Patients were stratified into three groups for 
analysis according to the period between transplantation 
and the initiation of Or tho clone OKT3 therapy as follows: 
group 1, Orthoclone OKT3 treatment started less than 
ten days postoperatively; group 2, Orthoclone OKT3 
treatment started ten days to 3 months postoperatively; 
group 3, Orthoclone OKT3 treatment started more than 3 
months postoperatively. 
The rationale for this stratification was detailed in our 
previous reports6 and will be briefly reiterated as to the 
current series of patients. 
Group I. Sixty-eight patients were started on a regi-
men of Orthoclone OKT3 therapy at a median of six days 
following transplantation. Forty-eight patients (71 %) in 
this group had some histological evidence of rejection, 
with lymphoid infiltration on biopsy. In the remaining 20 
cases (29%), the only apparent cause of hepatic allograft 
dysfunction in the immediate posttransplant period was 
ischemic injury or clinical primary graft nonfunction. In 
addition, 22 patients (32%) had concomitant evidence of 
renal impairment during the early posttransplant period, 
which precluded routine dosing with Cs. 
Group 2. Among the 73 patients in this group, Ortho-
clone OKT3 therapy was started at a median of 19 days 
posttransplantation. Sixty-four (88%) of the patients had 
histological evidence of rejection with secondary deterio-
ration of biochemical hepatic function parameters. In the 
remaining nine patients (12%), the primary cause of 
allograft dysfunction was determined to be cytomegalovi-
rus (CMV) hepatitis (four patients), persistent ischemic 
injury (four patients), and biliary obstruction due to 
biliary anastomotic leakage (one patient). 
Group 3. Orthoclone OKT3 therapy was started at 
an average of 420 days posttransplantation in the 16 
patients in this group. These patients had no evidence of 
ischemic damage or renal failure. Percutaneous biopsy 
Table 1. Comparison of Nonsignificant Parameters 
Between Orthoclone OKT3-Treated and Control 
Groups 
Orthoclone 
Parameter OKT3-Treated Control 
Age (yr) 28.6 23.3 
Sex (%) 
Male 43 45 
Female 57 55 
Presensitization 
(%PRA) 11.1 10.4 
Degree HLA match 1.28 1.10 
Values are expressed as means. 
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findings verified cell-mediated rejection in all patients, 
although the stigmata of chronic rejection were often 
present. 
Orthoclone OKT3 Administration 
The premedications and precautions used to diminish 
the side effects of Orthoclone OKT3 have not changed 
from the initial series.6 Even with heightened physician 
awareness regarding the possibility of severe pulmonary 
edema due to preexisting fluid overload,l.3 three of the 157 
treated patients required intubation and pressor support. 
All three patients were successfully extubated following 
the brief support period. 
Histopathological Criteria 
One hundred forty (89%) of the 157 patients treated 
with Orthoclone OKT3 had a percutaneous liver biopsy 
performed before or shortly after starting Orthoclone 
OKT3 therapy. The biopsy specimens were processed and 
analyzed according to criteria previously described.6 
Eighty-five of the 140 patients who had pretreatment 
biopsies had repeat biopsies at the termination of Ortho-
clone OKT3 therapy or shortly thereafter. 
Definition of Therapeutic Response 
A complete response to therapy in the hepatic allograft 
recipients treated with Orthoclone OKT3 was defined as 
a return of liver function to normal or near normal during 
or within the first 2 weeks following completion of thera-
py. A partial response was defined as' improvement of 
biochemical parameters, with or without objective histo-
logical improvement. Patients were assigned to the "no 
response" category if there was no improvement or wors-
ening of biochemical parameters. 
Statistical Methods 
Fisher's exact test was used to determine the statistical 
significance of pretreatment parameters such as age, sex, 
degree of sensitization, and the degree of HLA matching 
between the treated and control groups. Life-table analy-
ses were performed to determine both allograft and 
patient survival curves. A two-tailed P value of <.05 was 
considered statistically significant. 
RESULTS 
Patient Profile 
Table I compares several parameters of the 
157 Orthoclone OKT3-treated p'atients and 
the 320 control patients. Fifty-seven of the 
157 liver recipients were in the pediatric age 
range of 6 months to 18 years, and averaged 
6.8 ± 5.0 (SD) years. The average age for the 
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Orthoclone OKT3-treated group as a whole 
was 28.6 years v 23.4 years of age for the 
control group. One hundred thirty-five (86%) 
of the J 57 patients were undergoing their first 
grafts; the other 22 (14%) had undergone 
retransplantation before receiving a course of 
Orthoclone OKT3 .. 
All of the grafts used for hepatic recipients 
were selected without knowledge of the HLA 
types before transplantation. At the HLA A, 
B, and DR loci, the antigens matched aver-
aged 1.28 ± 0.99 (range, 0 to 4; maximum of 
6) v 1.10 ± 0.98 for the control group. The 
degree of presensitization, ie, percent reactiv-
ity against a random panel (PRA), was also 
not significantly different. The mean PRA 
was J 1.1 % for the treated group v 10.4% for 
the control group. Despite a positive T-cell 
crossmatch, the incidence of hepatic trans-
plantation in the Orthoclone OKT3 treatment 
group was 13% as compared with 17% in the 
control group. 
Response to Orthaclone OKT3 Therapy 
In keeping with our initial findings,6 the 
overall response rate of the 157 liver recipients 
treated with Orthoclone OKT3 was 79%, 
whereas 21% of those treated did not show 
objective improvement (Table 2). Eighty-five 
(54%) of those demonstrating a positive 
Table 2. Percent Response Rates to Orthoclone OKT3 
Treatment of Patients With Acute Hepatic Allograft 
Dysfunction 
No. Response Rates (%) 
Group' Patients Overall Full Partial None 
All groups-A 157 79 54 25 21 
All groups-B 128 85 58 25 17 
Group 1-A 68 71 38 33 29 
Group 1-8 48 76 43 33 24 
Group 2-A 73 88 69 19 12 
Group 2-8 64 94 72 22 6 
Group 3-A. -B 16 69 50 19 31 
* A, analysis of all patients treated with Orthoclone OKT3 
regardless of final determination of allograft dysfunction; 8. 
analysis of the corresponding group of patients as in A, except 
for deletion of that subset of patients where there was no 
evidence of rejection. 
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response to therapy had full reversal of bio-
chemical abnormalities, whereas 25% had a 
partial response. The highest response rate 
was in group 2 patients, where the incidence of 
objective improvement was 88%. This group 
also had the best "full" response rate, with 
69% of patients having resolution of all bio-
chemical parameters of rejection. 
In contrast, patients in group I, whose 
therapy was initiated within nine days post-
transplant, had only a 71 % response rate, of 
which a "full" response was achieved in only 
38% of the patients. The failure rate was 29%. 
Fifty percent of group 3 patients had a "full" 
response, whereas 19% had a partial response. 
The failure rate was 31 %. 
In order to better assess the response of 
hepatic allograft recipients with documented 
cell-mediated rejection to Orthoclone OKT3 
therapy, we also analyzed group 1, 2, and 3 
patients after eliminating a subset of patients 
whose graft dysfunction was ascribed exclu-
sively to causes other than cell-mediated 
rejection. Twenty-nine such patients were 
identified, 20 (69%) of whom were in group 1, 
. and nine (31 %) in group 2. Of the 20 patients 
in group 1 with nonrejection graft dysfunc-
tion, 15 cases (75%) were due solely to 
ischemic injury during procurement, and five 
(25%) were due to primary non function of the 
allograft. The causes of nonrejection graft 
dysfunction in the nine group 2 patients were 
previously listed under Materials and Meth-
ods. 
Elimination of these patients from analysis 
improved, but did not significantly alter, the 
response rates of any group (Table 2). The 
overall response rate of the remaining 128 
patients was 85%, with the "full," "partial," 
and "no response" rates being 58%, 25%, and 
17%, respectively. The response rate of group 
2 patients increased to 94%, with 72% having 
a "full" response and only 6% having "no 
response." The response rate of group I 
patients, who had evidence of cell-mediated 
rejection as the cause of allograft dysfunction, 
increased to 76%. Forty-three percent of these 
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patients had a "full" response, whereas only 
24% were considered to be treatment failures. 
Recurrence of Rejection and Impact 
on Retransplantation 
During the follow-up period that extended 
until February 1986, only 25 (20%) of the 125 
patients demonstrating a response to Ortho-
clone OKT3 therapy experienced further 
rejection episodes. The recurrent rejection 
episodes occurred a mean of 3.3 months and a 
range of 0.5 to 11.0 months following comple-
tion of Orthoclone OKT3 therapy. Sixteen 
(64%) of the 18 recurrent rejections were 
successfully treated with high-dose steroids, 
with return of normal hepatic function. Nine 
patients subsequently lost their grafts and 
required retransplanta tion. 
The impact of Orthoclone OKT3, in con-
junction with Cs and steroids, on the recurrent 
rejection rate is illustrated by the incidence of 
retransplantation. Among the control group, 
the incidence of retransplantation was 22.2%. 
This is in good agreement with our overall 
historical rates. Among all 157 patients 
treated with OrthocJone OKT3 for graft dys-
function, the incidence of retransplantation 
was 23.6%. Patients in group 2 had the lowest 
incidence of retransplantation, with only 12% 
requiring retransplantation. The retransplant 
rate in group 3 was 37%, whereas the rate of 
group 1 was 32%. When those patients w{th 
nonrejection causes of graft dysfunction were 
removed from analysis, the overall rate of 
retransplantation dropped to 15.9%. Thus, a 
total of 26 of the 29 patients in the subset of 
nonrejection-mediated allograft dysfunction 
required retransplantation. The correspond-
ing decreased retransplantation rate in group 
2 was 6.8%, whereas group 1 patients required 
retransplantation in 20.6% of cases. 
Impact of Orthoclone OKT3 on Allograft 
and Patient Survival 
A final consideration in evaluating a new 
immunosuppressive agent is the impact of the 
drug on overall allograft function and patient 
survival. Life-table analysis of allograft sur-
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vival among control patients v patients treated 
with Orthoclone OKT3 for all patients with 
hepatic allograft dysfunction due to acute 
rejection is shown in Fig 1. During the entire 
posttreatment period, a statistically signifi-
cant difference could be observed between the 
control group and the Orthoclone OKT3-
treated group (Table 3). For the control 
group, the 6-month graft survival rate was 
63%. In contrast, 80% of all allografts treated 
with Orthoclone OKT3 for graft dysfunction 
due to rejection continued to function at 6 
months (P < .005). At 1 year, the correspond-
ing figures were 55% and 64% for the control 
and treated groups, respectively (P < .01). 
Although the parameters affecting patient 
survival are multifactorial,8 one factor that 
has been linked to overall patient survival is 
rejection. Comparison of patient survival in 
the control group v the Orthoclone OKT3-
treated group reveals a. statistically significant 
improvement in the treated group at 6 months 
(74% v 83%, P < .02) (Fig 2). Although the 
data are not yet complete, there is a trend 
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Table 3. Comparison of Allograft and Patient Survival Between Orthoclone OKT3-Treated and Control Groups 
Allograft Survival (%) Pat"'"t Survival (%) 
Group 6ma 1yr Smo 1 yr 
Control 63.4 55.0 73.7 71.6 
Orthoclone OKT3-treated 
Overall 72.4 64.4 82.9 75..2 
(P < .003) (P< .01) (P< .01) (NS) 
Group 1 54.1 54.1 72.1 67.1 
(NS) (NS) (NS) (NS) 
Group 2 80.7 76.7 86.7 79.2 
(P < .003) (P < .003) (P < .005) (NS) 
Group 3 68.8 44.5 81.2 72.2 
(P < .05) (NS) (NS) (NS) 
Statistical comparison between patients with evidence of rejection treated with Orthoclone OKT3 and control patients. NS 
indicates that P > .05. 
toward improved patient survival in the 
treated group v the untreated group at 1 year 
(72% v 75%, P = NS). 
As indicated by the rate of reversal, the 
benefits of Orthoclone OKT3 treatment in 
group 2 patients with cell-mediated rejection 
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Fig 2. Comparison of patient survival between 
control group (dotted line) and all patients treated with 
Orthoclone OKT3 for rajection (solid lina'. P values 
were <.02 for all time points excapt for 1 year INS). as 
determined by life-table analysis. 
persisted during the analysis of long-term 
graft and patient survival. Allograft function 
in group 2 patients was 81% (v 59% for 
controls, P < .005) at 6 months, whereas 
function at 1 year was 77% (v 55% for con-
trols, P < .005) (Fig 3). Patient survival also 
appeared to improve during the same period. 
Overall, 87% of pa tients in group 2 were. alive 
after 6 months (v 74% for controls, P < .01), 
and a definite, although statistically nonsig-
nificant, difference was noted at 1 year (72% v 
79% for controls and group 2 patients, respec-
tively). 
Group 1 patients constitute a subset of 
Orthoclone OKT3-treated patients with con-
comitant renal and hepatic dysfunction. 
Despite the historically poor prognosis of this 
group, these patients appeared to benefit from 
the use of Orthoclone OKT3 when rejection 
was involved in posttransplantation hepatic 
allograft dysfunction. Allograft function in 
the control group was similar to that of group 
1 at the end of 1 year (55% v 54%, respec-
tively) (Fig 3). In addition, normalization of 
patient survival of group 1 patients (67%) to 
that of the control group (72%) was noted. 
Morbidity and Mortality 
As we have previously reported,9 it is often 
difficult to ascribe the death of a patient to 
any single given cause. Nevertheless, systemic 
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Fig 3. Breakdown of allograft survival curves 
between control group (dotted line. square dots) and 
group 2 patients (solid line) v group 1 patients (dotted 
line. round dots) treated with Orthoclone OKT3 for 
rejection. P value. were <.003 for all time points when 
comparing group 2 and control curve •. 
sepsis accounted for 55% of deaths in the 
present study. This was generally due to the 
consequences of aggressive immunosuppres-
sion. Bacterial sepsis was predominant, fol-
lowed by overwhelming fungal and viral infec-
tions. Unremitting cell-mediated rejection 
appeared to playa significant role in mortality 
in approximately 33% of these patients. 
Ischemic graft injury in the perioperative 
period, as well as primary graft nonfunction, 
were considered contributing factors in 28% 
of all mortalities, and occurred more often in 
group 1 deaths than in group 2 deaths (79% v 
21 %, respectively). Technical factors were 
involved in approximately 20% of mortalities, 
and included vascular thrombosis and biliary 
sepsis due to anastomotic breakdown. Finally, 
several miscellaneous causes of death were 
noted, including recurrent metastatic carci-
noma (4%), cerebral vascular accident (8%), 
and myocardial infarction (4%). It should be 
noted that any combination of causes may 
have occurred in a given mortality. 
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Analysis of the morbidity associated with 
the administration of Orthoclone OKT3 to 
liver transplant recipients revealed a pattern 
similar to that previously reported.6 Table 4 
lists the incidence of side effects observed with 
Orthoclone OKT3. Hemodynamic instability 
in the form of transient changes in the BP or 
heart rate occurred most often. Fever, nausea, 
vomiting, diarrhea, dyspnea, and chills were 
also common. These adverse reactions 
appeared most frequently during the first few 
days of Orthoclone OKT3 therapy, presum-
ably due to the release of vasoactive sub-
stances during T-cell destruction. 1.3 No deaths 
were directly attributable to these side 
effects. 
Infectious complications, generally limited 
to acquired urinary tract infections, herpes 
zoster reactivation, and wound infections, 
were not considered major infections. Nev-
ertheless, major infections occurred in 22% of 
treated patients and were often manifested as 
bacterial, fungal, or parasitic pneumonias, 
viral hepatitis, or systemic sepsis. In 56% of 
these patients, major infections played a role 
in mortality. 
DISCUSSION 
Orthoclone OKT3 is a murine monocional 
anti-human T cell antibody with clinically 
proven efficacy in the reversal of acute renal 
allograft rejection. I-3 Although it has been 
approved by the Food and Drug Administra-
tion for reversal of acute renal allograft rejec-
tion, we have previously demonstrated that 
Orthoclone OKT3 is also efficacious in the 
Table 4. Morbidity Associated With 
Orthoclone OKT3 Use 
Side Effects 
Hemodynamic instability 
Fever 
Gastrointestinal disturbances 
Dyspnea 
Chills 
Anaphylactoid reactions 
Infections 
Major 
Minor 
Patients (%) 
77 
70 
63 
41 
31 
2 
22 
45 
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reversal of hepatic allograft rejection.4•6 The 
findings of our initial study, which have been 
verified by other centers,S suggest that the use 
of Orthoclone OKT3 in conjunction with Cs 
and steroids is associated with a high reversal 
rate of allograft rejection unaccompanied by 
the high incidence of recurrent rejection seen 
in the early studies. The purpose of this study 
was to analyze the long-term impact of Ortho-
clone OKT3 on hepatic allograft function as 
well as its effect on patient survival. 
In agreement with our previous findings, 
Orthoclone OKT3 was shown to be effective 
in reversing acute hepatic allograft rejection. 
The rates of reversal for groups 1, 2, and 3 
. were similar to those previously reported.6 In 
addition, this study verified our initial impres-
sion that patients who have the best response 
to Orthoclone OKT3 are those in whom cell-
mediated rejection is the primary cause of 
postoperative liver allograft dysfunction. The 
less than optimal response rates seen in groups 
1 and 3 reflect concomitant processes (ie, an 
element of coexisting ischemic injury and 
renal failure in group 1, and a degree of 
chronic rejection seen in group 3). 
Cosimi et al5 described their initial findings 
on the use of Orthoclone OKT3 in hepatic 
allograft rejection with a similar but more 
limited protocol. Specifically, treatment in 
their study was limited to patients who corre-
sponded to our group 2 patients (ie, between 
seven and 30 days posttransplant). They 
report a full reversal of rejection parameters 
in 80% of the 25 patients studied. This is in 
good agreement with the 92% response rate 
and 72% full-reversal rate observed in our 
corresponding population. 
Regardless of the good response rates seen 
in group 2 patients, it could be argued that the 
maximal benefit of this new immunosuppres-
sive agent will be achieved in those patients 
who have done poorly historically. These 
patients manifest hepatic allograft dysfunc-
tion in the early posttransplant period and 
usually have a spectrum of metabolic 
derangements that make them poor operative 
candidates. Although Orthoclone OKT3 will 
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not benefit those patients with hepatic dys-
function due to primary graft nonfunction or 
ischemic injury alone, we have demonstrated 
that it may help those patients with an ele-
ment of rejection (in addition to coexisting 
renal failure) or ischemic injury. Graft func-
tion in this group of patients appears to nor-
malize toward control figures following treat-
ment. 
One major impact of Orthoclone OKT3 on 
hepatic transplantation has been a low inci-
dence of recurrent rejection following reversal 
of rejection. Approximately 20% of patients 
who had objective improvement in their rejec-
tion parameters had a subsequent rejection 
episode following completion of Orthoclone 
OKT3 therapy. Further immunosuppressive 
treatment successfully reversed 64% of recur-
rent rejection episodes, whereas the remaining 
36% required retransplantation. 
Because of the efficacy of Orthoclone 
OKT3 in the reversal of rejection, there 
appears to be a diminished requirement for 
retransplantation in those patients whose allo-
graft dysfunction was caused by rejection. 
The major factor influencing retransplanta-
tion has been rejection.10 The overall rate of 
retransplantation was 16%, as compared with 
22% for the control group. The best results 
have been obtained in the subset of patients 
corresponding to those with acute rejection, 
namely, group 2 patients in whom the rate of 
retransplantation was 7%. This rate compares 
favorably with those figures reported by 
Cosimi et aV who cited a retransplantation 
rate of 4% in their group of patients that 
roughly corresponded to our group 2 patients. 
The high rate of retransplantation (38%) seen 
in group 3 patients reflects the inability of 
Orthoclone OKT3 to reverse the stigmata of 
chronic rejection (ie, obliterative arteriolar 
lesions, loss of intrahepatic bile ducts, and 
portal fibrosis).6 Nevertheless, Orthoclone 
OKT3 has been able to extend the functional 
use of group 3 allografts before the need for 
retransplantation. 
The decreased need for retransplantation is 
also evidenced by the overall functional sur-
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vival of hepatic allografts. Using life-table 
analysis, a statistically significant improve-
ment in overall allograft survival could be 
demonstrated. The major benefit was seen 
principally in group 2 patients, whose graft 
survival increased by more than 20%. The 
allograft survival of group 1 patients approxi-
mated that of the control group. 
Although patient survival is multifactorial, 
the most important parameter is the need for 
retransplantation. Thus, a reduced need for 
retransplantation should correlate with im-
proved patient survival. Indeed, by life-table 
analysis, it appears that such a trend did exist. 
A statistically significant improvement in 
patient, survival could be demonstrated in 
group 2 patients as compared with the control 
group at 6 months following completion of 
Orthoclone OKT3 therapy. 
Long-term patient survival is also depen-
dent on other parameters, such as vulnerabil-
ity to infections. Although the majority of side 
effects associated with Orthoclone OKT3 
therapy were acute but mild and largely lim-
ited to the duration of treatment, late-
appearing infections with with Pneumocystis 
carinii and other opportunistic organisms, as 
well as viral hepatitis, may be related to a 
longer lasting effect of Orthoclone OKT3 on 
the immune responsiveness of the host. 
Although this is of only theoretical interest at 
present, a more detailed study will be needed 
to explore this issue. 
The findings presented in this report sug-
. FUNG ET Al 
gest that Orthoclone OKT3 has favorably 
affected the overall success of liver transplan-
tation in patients with documented liver allo-
graft rejection with respect to both allograft 
and patient survival. The normalization of 
survival curves in group 1 patients suggests 
that Orthoclone OKT3 may also playa role in 
these critically ill patients, by adding a mea-
sure of treatment for early rejection and/or 
prophylaxis in patients in whom Cs therapy 
must be cautiously withdrawn or lowered. 
Thus, prudent use of Orthoclone OKT3 in 
conjunction with Cs and steroids has 
improved our ability to treat hepatic allograft 
rejection. 
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